To date, the CLEVER-ACS clinical trial (NCT01529554) is the only study that aims to translate the idea of targeting mTOR activity in myocardial infarction into the clinical setting while laying a specific focus on the immunomodulatory function of mTOR inhibition. The gene discussed is MTOR; the disease is myocardial infarction.